Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/68423
標題: Cyr61 increases migration and MMP-13 expression via alpha v beta 3 integrin, FAK, ERK and AP-1-dependent pathway in human chondrosarcoma cells
作者: Tan, T.W.
Yang, W.H.
Lin, Y.T.
Hsu, S.F.
Li, T.M.
Kao, S.T.
Chen, W.C.
Fong, Y.C.
Tang, C.H.
關鍵字: growth-factor
signaling pathways
breast-cancer
matrix
metalloproteinases
tumor progression
up-regulation
lung-cancer
ccn
family
invasion
transduction
期刊/報告no:: Carcinogenesis, Volume 30, Issue 2, Page(s) 258-268.
摘要: Cysteine-rich 61 (Cyr61), from the CCN gene family, is a secreted and matrix-associated protein, which is involved in many cellular activities such as growth and differentiation. However, the effect of Cyr61 on migration activity in human chondrosarcoma cells is mostly unknown. Here, we found that Cyr61 increased the migration and expression of matrix metalloproteinase (MMP)-13 in human chondrosarcoma cells (JJ012 cells). RGD peptide, alpha v beta 3 monoclonal antibody and mitogen-activated protein kinase (MEK) inhibitors (PD98059 and U0126) but not RAD peptide inhibited the Cyr61-induced increase of the migration and MMP-13 upregulation of chondrosarcoma cells. Cyr61 stimulation increased the phosphorylation of focal adhesion kinase (FAK) and extracellular signal-regulated kinase (ERK). In addition, activator protein-1 (AP-1) decoy oligodeoxynucleotide also suppressed the MMP-13 messenger RNA and enzyme activity enhanced by Cyr61. Moreover, Cyr61 increased the binding of c-Fos and c-Jun to the AP-1 element on the MMP-13 promoter. Taken together, our results indicated that Cyr61 enhances the migration of chondrosarcoma cells by increasing MMP-13 expression through the alpha v beta 3 integrin receptor, FAK, ERK, c-Fos/c-Jun and AP-1 signal transduction pathway.
URI: http://hdl.handle.net/11455/68423
ISSN: 0143-3334
文章連結: http://dx.doi.org/10.1093/carcin/bgn284
Appears in Collections:期刊論文

文件中的檔案:

取得全文請前往華藝線上圖書館



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.